Tianjin Medical University

Tianjin, China

Tianjin Medical University was founded in 1951; was the first medical institution approved by the State Council of the People's Republic of China. Hsien-I Chu, a renowned endocrinologist, was the first president of the university. The current president is Yongfeng Shang.In December 1993, with the approval of the State Education Council, the Tianjin Medical College and the Tianjin Second Medical College were integrated into the Tianjin Medical University. In December 1996, the university was accepted into Project 211, so it became one of the 97 key institutions in which there are 9 medical institutions that will be constructed emphatically by the State.In 1981, the university was approved by the Academic Degree Committee of State Council to confer the Doctorate Degree, Master's Degree and Bachelor's Degree and in 1988, was permitted to set up seven-year medical program.It is listed in International Medical Education Directory . Wikipedia.

Time filter
Source Type

News Article | May 22, 2017
Site: en.prnasia.com

BEIJING, May 22, 2017 /PRNewswire/ -- As we get older, we are not only increasingly eager to maintain our young look, but we also hope that our brain response and memory remain good as well. Fortunately, with the development of science and technology, the scientific research products dealing with brain health of the middle-aged and elderly might make it possible to "keep the brain spry". During the 13th China Nutrition Science Congress held by the Chinese Nutrition Society, Nestle launched "Nestle YIYANG Fuel for brainTM senior milk powder" a new innovative product in the Chinese market. The product is specially designed to help people over 50 years old "refuel their brains and start a new smart life". Developing a healthy lifestyle and protecting your brain as you age China is facing a very grim aging trend. As shown by 2010 demographic census data, the population over the age of 50 accounted for 28.3% of the total population; as of 2016, there were 350 million people over 50 years old, accounting for 25% of the total population; by 2050, this proportion may reach 50%. According to Wenhua ZHAO, deputy director of National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, the aging of the population, or extended average life expectancy, is the inevitable result of societal progress and development. Middle-aged people and the elderly should pay attention to a balanced intake of nutrients and development of a healthy lifestyle. According to scientific research, the human brain does not produce its energy, it needs to take in glucose, which is the main energy source, continuously from blood as fuel. When people get older, they tend to have slower reaction times, decreased memory and sometimes they feel their brain cannot fully function. This may be partially associated with the fact that as we age, glucose intake ability and use decreases so that the brain cannot get enough fuel to function optimally. Another alternative source of brain energy comes from ketone, i.e., when there is lack of energy, ketone as the metabolite of fat, can be taken as alternative energy directly for brain. Guowei HUANG, brain health expert and dean of School of Public Health, Tianjin Medical University said, "Compared with healthy young people, the brain of the elderly utilizes glucose at only 85-90% the rate of young people while patients with Alzheimer's disease utilize only around 75%. Studies have shown that medium chain triglyceride (MCT) can be converted into ketone bodies and serve as an alternative source of energy for the minds of the elderly." Experts believe that reasonable nutritional supplements for the brain help to delay aging and prevent and control various geriatric diseases, so as to achieve the goal of good health and longevity and improved quality of life. Compared with long chain triglyceride, MCT (medium chain triglyceride) is easier for intake and metabolism. It can rapidly release energy to quickly provide the brain with energy and nutrients. In the case of under-utilization of glucose, MCT can directly supply energy to the brain in lieu of glucose, supporting the brain's normal energy needs without being stored as fat in the body. MCT naturally exists in lauric oils such as coconut oil, which is a natural plant source ingredient. MCT has been early applied in medical care products with special needs, like milk powder for premature babies, sports energy products etc. Additionally, MCT has shown potential in research in the treatment of neurodegenerative diseases such as Alzheimer's disease. "Nestle YIYANG Fuel for brainTM senior milk powder" contains MCT which can be efficiently converted into ketone, the energy required by brain, to 'feed' the brain. This is why the milk powder is named "Fuel for Brain," said Marianne Tsanis, vice president of Dairy Business Unit, Nestle Greater China. At present, Chinese people tend to place great emphasis on treatment while placing little emphasis on prevention; however, prevention is more important than treatment for chronic disease management. As a world leader in "Nutrition, Health and Wellness", Nestle is deeply aware that with an increase of age, people need to pay more attention to their daily nutrition intake. Dr. Fabrizio Arigoni, head of Nestle Research Center Asia, will deliver a speech on the challenges of aging from a nutrition and health viewpoint at Aging Nutrition and Successful Aging Session of China Nutrition Science Congress and will emphasize the role that diet can play in preventing the onset of age related diseases.  After 50 years old of age, people particularly need nutritious food that meets their age characteristics so as to maintain good health and quality of life. To care for the elderly, in addition to encouraging them to actively participate in physical fitness activities, it is equally important to help them supplement nutritions and build a scientific nutrition structure. The launch of "Nestle YIYANG Fuel for brainTM senior milk powder" is another move to express deep concern for the elderly. Nestle has specially put forward a new concept of "happy aging" for people above 50 years old. Under this concept, the middle-aged and the elderly are encouraged to actively pursue quality of life and merrily enjoy their life. "As an old Chinese saying goes, 'Diet cures more than the doctors'. Nestle YIYANG has always been committed to providing healthy ideas and nutrition programs for people above 50 years old. We advocate the middle-aged and the elderly to be more proactive in managing their own health, and we also call on everyone no matter what age to pay more attention to their nutrition and health," said Marianne Tsanis, vice president of Dairy Business Unit, Nestle Greater China. As the largest food company and a leading company committed to "Nutrition, Health and Wellness", Nestle has been providing nutritious and healthy food for consumers for more than 150 years. Relying on its industry leading research and development capabilities, the network that comprises of 40 centers, Nestle tailors nutrient formula of dairy products for population groups of various ages. Nestle YIYANG is tailored for Chinese consumers above 50 years old according to their physical characteristics with an aim to provide them with better health and more vitality and enable more possibilities. Nestle YIYANG has launched three milk powder products for middle-aged and elderly in China, i.e., Nestle YIYANG Jianxin Gold 2-in-1 Formula Senior milk powder, Nestle YIYANG Omega 3:6 Jianxin Senior milk powder and Nestle YIYANG Protects(Yi Hu Yin Zi)Senior milk powder Plus the newly launched " Nestle YIYANG Fuel for brainTM senior milk powder", Nestle YIYANG brand has had four milk powder for middle-aged and the elderly for bones, heart, digestive health and cognitive ability, all of which are the health problems most concerned about by people above 50 years old. Nestle YIYANG cherishes the demand of middle-aged and elderly people to pursue "happy aging" and helps these people above 50 years old to have a longer and younger state through reasonable dietary nutrition and a healthy lifestyle.

MRI is one of the most widely used, noninvasive and versatile imaging tools for clinical detection, staging and monitoring of malignancy, without the need for ionizing radiation or harmful radionuclides. The most frequently employed contrast agents used in MRI are gadolinium (Gd)-based, since they do not provoke an immune response in cells. However, such compounds require high doses of intravenous administration and are retained in the body's organs. In the search for alternative, Han and colleagues focused on proteins, which are naturally occurring nanomaterials. For example, the protein-bound nanoparticle Abraxane can be used to treat metastatic breast cancer. In the same way, protein scaffolds that encapsulate metal-based nanoparticulate contrast agents also appear to enhance the effectiveness of contrast agents. In a paper published June 26 in Nano Letters, ACS Publications, Han and colleagues outlined how human transferrin (Tf) proteins can be used to create an MRI contrast nanoprobe by mimicking the natural process to form special nanoparticles called gadolinium biomineralized human transferrin protein-based nanoparticles or Gd@TfNP. "The Gd@TfNPs preserve the functions of Tf very well, possess superior chemical and physical properties, and are brighter compared to the Gd-based agents currently in use," Han said, adding that the nanoparticles could also be used as tumor-targeting and systematically clearable contrast agents for MR detection of early-stage tumors. "Such probes can immediately leave the tumor sites after delivery and we could track the overall process by MRI. Such a technique might be useful not only for visualizing tumor therapies, but for optimizing drug dose and evaluating clinical results," said Yang Zhao, MD, PhD, of the Second Hospital of Tianjin Medical University and the paper's first author. Explore further: Better contrast agents based on nanoparticles More information: Yang Zhao et al, Tumor-Targeted and Clearable Human Protein-Based MRI Nanoprobes, Nano Letters (2017). DOI: 10.1021/acs.nanolett.7b00828

BETHESDA, Md., Aug. 01, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) is pleased to announce that Dr. Chuanhai Cao has joined its medical research team as a key Advisor. Dr. Cao is Associate Professor of Pharmaceutical Sciences, at the University of South Florida’s (USF) College of Pharmacy. He also has joint appointments as Associate Professor at USF’s department of Neurology at the College of Medicine, and the department of CMMB at the College of Arts and Sciences. “The addition of Dr. Cao will accelerate IGC’s efforts to move its Alzheimer’s product Hyalolex to clinical trials.  Dr. Cao is a dynamic force in cannabis related therapies for Alzheimer’s disease. Dr. Cao has one co-inventor patent that has been approved for medical trials, and another patent that is currently being worked on for an Investigational New Drug (IND) application with the FDA.  Dr. Cao is the perfect researcher to assist us in moving our THC-based Alzheimer’s treatment into trials and potentially into a blockbuster product.  The addition of Dr. Cao to the core group of medical and science advisors consisting of Dr. Craig Cheifetz, Dr. Ranga Krishna and Dr. James Saunders greatly strengthens our team as we seek to move our four products towards commercialization,” concludes Ram Mukunda, CEO. Dr. Cao conducted the research underlying USF’s patent filing for the use of THC as a potential therapeutic agent for Alzheimer’s. The lab experiments using an animal model led to the publication of findings that THC has the potential to inhibit amyloid beta peptide aggregation and possibly restore memory function, halting the progression of Alzheimer’s disease.  IGC recently acquired exclusive rights to this patent filing from USF. Dr. Cao has a PhD, in Medical Microbiology and Virology, from Tianjin Medical University, China.  He has authored or co-authored around 80 peer-reviewed articles.  He has been quoted in Huffington Post, USA Today, and was featured in the CNN documentary WEED 3 The Marijuana Revolution by Dr. Sanjay Gupta. Dr. Cao’s interview can be viewed at https://vimeo.com/137431143#t=1818s. “I became particularly interested in Alzheimer’s disease, especially after the diagnoses of a few individuals close to me.  In 2001, led by co-authors, including well-respected Alzheimer’s pathology researchers at USF, I contributed to my (then) first published paper on responses in experimental mice to a vaccination for the Alzheimer’s disease-associated beta amyloid 1-42 peptide.  I would then go on to co-author over 10 papers studying beta amyloid in Alzheimer’s mice, with a focus on potential treatments.  In 2008, I helped to first-author two papers reporting on potential vaccines for Alzheimer’s disease. The first described the studying and adjuvant-free vaccination using mutated amyloid beta peptides, and the second tested mutant amyloid-beta-sensitized dendritic cells as a possible vaccine. I was also head of a patent on amyloid beta peptides and methods of use. In 2012, I first-authored a book chapter on amyloid beta vaccination strategies, and am currently pursuing a patent on immunomodulatory cells as a novel treatment for diseases, in addition to researching the use of cannabinoids for preventing amyloid beta aggregation.” stated Dr. Cao. About IGC IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats. In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us. Follow us on Twitter @IGCIR and Facebook.com/IGCIR/. Forward-looking Statements Please see forward looking statements as discussed in detail in IGC's Form 10 K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Tumors consistently mimic wound-generating chronic inflammation; however, why they do not heal like wounds with fibrotic scars remains unknown. The components of the tumor microenvironment, such as transforming growth factor β (TGF-β) and fibroblast growth factors (FGFs), may account for this phenomenon. Tumor formation involves continuous activation of the FGF pathway, whereas the repair of tissue injury is a self-limiting process accompanied with controlled activation of the FGF pathway. In the tumor microenvironment TGF-β increases the secretion of FGFs, further promoting the malignant biological properties of tumors. However, during wound healing, sufficient TGF-β together with moderate FGFs lead to matrix deposition and the formation of fibrotic scars. In the present study, TGF-β1 combined with AZD4547, an FGF receptor (FGFR) inhibitor, transformed hepatoma cells into less malignant fibroblast-like cells with respect to morphology, physiological properties, and gene expression profiles. In vivo experiments showed that TGF-β1 combined with AZD4547 not only inhibited tumor growth but also promoted tumor parenchyma fibrosis. Our results indicate that FGFR inhibitor treatment converts the effect of TGF-β on the hepatocellular carcinoma cells from tumor promotion into tumor inhibition by enhancing the induction effect of TGF-β on some fibroblast-associated genes. Converting human liver cancer cells into less malignant fibroblast-like cells and inducing tumor parenchyma cell fibrosis provides an alternative strategy for limiting tumor progression.Oncogene advance online publication, 6 March 2017; doi:10.1038/onc.2016.512. © 2017 Macmillan Publishers Limited, part of Springer Nature.

Chen D.,Tianjin Medical University
Arteriosclerosis, Thrombosis, and Vascular Biology | Year: 2017

OBJECTIVEW—: Angiogenesis is a hallmark of embryonic development and various ischemic and inflammatory diseases. Prostaglandin E2 receptor subtype 3 (EP3) plays an important role in pathophysiologic angiogenesis; however, the precise mechanisms remain unknown. Here, we investigated the role of EP3 in zebra fish embryo and mouse retina angiogenesis and evaluated the underlying mechanisms. APPROACH AND RESULTS—: The EP3 receptor was highly expressed in the vasculature in both zebra fish embryos and murine fetal retinas. Pharmacological inhibition or genetic deletion of EP3 significantly reduced vasculature formation in zebra fish embryos and mouse retinas. Further characterization revealed reduced filopodia extension of tip cells in embryonic retinas in EP3-deficient mice. EP3 deletion activated Notch activity by upregulation of delta-like ligand 4 expression in endothelial cells (ECs). Inhibition of Notch signaling rescued the angiogenic defects in EP3-deficient mouse retinas. Moreover, EP3 deficiency led to a significant increase in β-catenin phosphorylation at Ser675 and nuclear accumulation of β-catenin in ECs. Knockdown or inhibition of β-catenin restored the impaired sprouting angiogenesis resulting from EP3 deficiency in ECs. The EP3 receptor depressed protein kinase A activity in ECs by coupling to Gαi. Inhibition of protein kinase A activity significantly reduced Ser675 phosphorylation and nuclear translocation of β-catenin, abolished the increased delta-like ligand 4 expression, and subsequently restored the impaired angiogenic capacity of EP3-deficient ECs both in vitro and in vivo. CONCLUSIONS—: Activation of the EP3 receptor facilitates sprouting angiogenesis through protein kinase A–dependent Notch signaling, suggesting that EP3 and its downstream pathways maybe potential therapeutic targets in the treatment of ischemic diseases. © 2017 American Heart Association, Inc.

He J.,Tianjin Medical University
Stroke | Year: 2017

BACKGROUND AND PURPOSE—: Atrial cardiomyopathy is associated with an increased risk of ischemic stroke. P-wave terminal force in lead V1, P-wave duration, and maximum P-wave area are electrocardiographic parameters that have been used to assess left atrial abnormalities related to developing atrial fibrillation. The aim of this systematic review and meta-analysis was to examine their values for predicting ischemic stroke risk. METHODS—: PubMed and EMBASE databases were searched until December 2016 for studies that evaluated the association between P-wave indices and stroke risk. Both fixed- and random-effects models were used to calculate the overall effect estimates. RESULTS—: Ten studies examining P-wave terminal force in lead V1, P-wave duration, and maximum P-wave area were included. P-wave terminal force in lead V1 was found to be an independent predictor of stroke as both a continuous variable (odds ratio [OR] per 1 SD change, 1.18; 95% confidence interval [CI], 1.12–1.25; P<0.0001) and categorical variable (OR, 1.59; 95% CI, 1.10–2.28; P=0.01). P-wave duration was a significant predictor of incident ischemic stroke when analyzed as a categorical variable (OR, 1.86; 95% CI, 1.37–2.52; P<0.0001) but not when analyzed as a continuous variable (OR, 1.05; 95% CI, 0.98–1.13; P=0.15). Maximum P-wave area also predicted the risk of incident ischemic stroke (OR per 1 SD change, 1.10; 95% CI, 1.04–1.17). CONCLUSIONS—: P-wave terminal force in lead V1, P-wave duration, and maximum P-wave area are useful electrocardiographic markers that can be used to stratify the risk of incident ischemic stroke. © 2017 American Heart Association, Inc.

BACKGROUND AND PURPOSE—: Intracerebral hemorrhage (ICH) is a neurologically destructive stroke, for which no valid treatment is available. This preclinical study examined the therapeutic effect of PD-L1 (programmed death ligand 1), a B7 family member and a ligand for both PD-1 (programmed death 1) and B7-1 (CD80), in a murine ICH model. METHODS—: ICH was induced by injecting autologous blood into 252 male C57BL/6 and Rag1 mice. One hour later, ICH mice were randomly assigned to receive an intraperitoneal injection of vehicle, PD-L1, or anti–PD-L1 antibody. Neurological function was assessed along with brain edema, brain infiltration of immune cells, blood–brain barrier integrity, neuron death, and mTOR (mammalian target of rapamycin) pathway products. RESULTS—: PD-L1 significantly attenuated neurological deficits, reduced brain edema, and decreased hemorrhage volume in ICH mice. PD-L1 specifically downsized the number of brain-infiltrating CD4 T cells and the percentages of Th1 and Th17 cells but increased the percentages of Th2 and regulatory T cells. In the PD-L1–treated group, we observed an amelioration of the inflammatory milieu, decreased cell death, and enhanced blood–brain barrier integrity. PD-L1 also inhibited the mTOR pathway. The administration of anti–PD-L1 antibody produced the opposite effects to those of PD-L1 in ICH mice. CONCLUSIONS—: PD-L1 provided protection from the damaging consequences of ICH. © 2017 American Heart Association, Inc.

Yang J.,Tianjin Medical University | Zhang W.,University of Houston
Current Opinion in Oncology | Year: 2013

PURPOSE OF REVIEW: Recent translational studies in osteosarcoma are discussed with the purpose to shed light on the new molecular therapeutic targets. RECENT FINDINGS: The genetic aberrations of vascular endothelial growth factor (VEGF), mammalian target of rapamycin, Wnt signaling pathway, the inactivation of p53, Rb, WWOX genes, and amplification of APEX1, c-myc, RECQL4, RPL8, MDM2, VEGFA might be involved in the pathogenesis of osteosarcoma. The promising therapeutic targets for osteosarcoma patients include: integrin, ezrin, statin, NOTCH/HES1, matrix metalloproteinases (MMPs), m-calpain, and Src, which are involved in tumor cell invasion and metastasis; aldolase A, fructose-bisphosphate, sulfotransferase family 3A, member 1, BCL2-associated athanogene 3, heat shock protein 70 (HSP70), B-cell lymphoma 2-interacting mediator (BIM), polo-like kinase 1, hypoxia inducible factor 1, alpha subunit, minibrain-related kinase, Bcl-xl, caspase-3, midkine, high mobility group box 1 protein (HMGB1), and Beclin1, which are involved in tumor proliferation and apoptosis; met proto-oncogene (hepatocyte growth factor receptor), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, insulin-like growth factor (IGF)-1R, fms-related tyrosine kinase 4, platelet-derived growth factor receptor, beta polypeptide, IGF-I/II, and c-kit, which are involved in tumor growth; endosialin, VEGF, thrombin, and MMPs, which are involved in tumor angiogenesis; transforming growth factor-α/β, parathyroid hormone-like hormone, interleukin-6, interleukin-11, receptor activator of nuclear factor-κB ligand, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, and cathepsin, which are involved in osteoclast function; Myc, HSP90, p-Met, p-Akt, p-STAT3, and cyclin D1, which are transcriptional factors; p-GP, hydroxysteroid (17-beta) dehydrogenase 10, HMGB1, BIM, inorganic phosphate, Bcl-2, PARP, mdm2, p21, Bax, and mitogen-activated protein kinase 1, which are involved in drug sensitivity. Furthermore, microRNAs such as miR-215 are also therapeutic targets. SUMMARY: These translational studies in osteosarcoma have identified new molecular targets for osteosarcoma. Copyright © Lippincott Williams & Wilkins.

Wang X.,Tianjin Medical University
British Journal of Cancer | Year: 2014

Background:Syndecan-1 (Sdc-1) shedding induced by matrix metalloproteinase-7 (MMP-7) and additional proteases has an important role in cancer development. However, the impact of Sdc-1 shedding on chemotherapeutic resistance has not been reported.Methods:We examined Sdc-1 shedding in colorectal cancer by enzyme-linked immunosorbent assay (ELISA), Dot blot, reverse transcription-PCR (RT-PCR), immunohistochemistry and so on, its impact on chemotherapeutic sensitivity by collagen gel droplet embedded culture-drug sensitivity test (CD-DST) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and potential mechanisms of action by Dot blot, western blot and immunofluorescence.Results:Sdc-1 shedding was increased in colorectal cancer patients, Sdc-1 serum levels in postoperative patients were lower than in preoperative patients, but still higher than those observed in healthy adults. Patients with high preoperative Sdc-1 serum levels were less responsive to 5-Fluorouracil, Oxaliplatin, Irintecan, Cisplatin or Paclitaxel chemotherapy. Moreover, the disease-free survival of patients with high preoperative Sdc-1 serum levels was significantly poorer. The possible mechanism of chemotherapy resistance in colorectal cancer can be attributed to Sdc-1 shedding, which enhances EGFR phosphorylation and downstream signalling.Conclusions:Shed Sdc-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer, and Sdc-1 serum levels could be a new prognostic marker in colorectal cancer.British Journal of Cancer advance online publication, 16 October 2014; doi:10.1038/bjc.2014.493 www.bjcancer.com. © 2014 Cancer Research UK

Gao Y.,Tianjin Medical University
International journal of nanomedicine | Year: 2011

RNA interference is a powerful method for the knockdown of pathologically relevant genes. Small interfering RNAs (siRNAs) have been widely demonstrated as effective biomedical genetic-therapy applications for many diseases. Unfortunately, siRNA duplexes are not ideal drug-like molecules. Problems hindering their effective application fundamentally lie in their delivery, stability, and off-target effects. Delivery systems provide solutions to many of the challenges facing siRNA therapeutics. Due to some fatal disadvantages of viral vectors, nonviral carriers have been studied extensively. Aside from liposomes, nanoparticles and cationic polymer carriers have exhibited improved in vivo stability, better biocompatibility, and efficiency for gene silencing with less cellular toxicity. They may represent a promising strategy for siRNA-based therapies, especially as nanomaterials. The present review also summarizes other methods of siRNA delivery and the side effects of the nanoparticles.

Loading Tianjin Medical University collaborators
Loading Tianjin Medical University collaborators